Academic Journal
Q2Chemical Biology and Drug Design
About Chemical Biology and Drug Design
About Chemical Biology and Drug Design
Chemical Biology and Drug Design is a peer-reviewed scholarly journal published by 23 (United Kingdom). It focuses on Q2. Publication coverage spans 2006-2026.
Key indicators: ISSN 1747-0285, 1747-0277; H-index 102.
Understanding This Journal's Metrics
Journal metrics help researchers assess fit, but they must be interpreted in context:
- H-index (102): Exceptionally high — 102 articles have each been cited at least 102 times. This indicates deep, sustained influence in the field.
Publishing in Chemical Biology and Drug Design
An established venue in its field. The journal welcomes solid, well-executed research. Ensure your manuscript fits the stated scope and follows author guidelines carefully.
- Scope fit: Confirm your research aligns with Q2. Off-scope manuscripts are typically desk-rejected quickly.
- Author guidelines: Follow formatting, reference style, and article-type requirements exactly — non-compliant manuscripts may be returned without review.
Is This Journal Right for Your Paper?
- Audience match: Will the journal's readers cite and build on your findings?
- Timeline: Higher-tier journals mean longer review and higher rejection risk. Balance prestige against your schedule.
- Indexing: Confirm indexing in Web of Science, Scopus, and PubMed (if biomedical) meets your institutional requirements.
- Open access needs: Check funder mandates and whether the journal offers compliant OA options.
Frequently Asked Questions
What is the ISSN of Chemical Biology and Drug Design?
1747-0285, 1747-0277.
Who publishes Chemical Biology and Drug Design?
23.
What are Chemical Biology and Drug Design's metrics?
H-index 102.
Is Chemical Biology and Drug Design peer-reviewed?
Yes — it is a peer-reviewed scholarly journal indexed in major academic databases.
Source-backed journal facts
Topics in published research
Computational Drug Discovery Methods; Synthesis and biological activity; Chemical Synthesis and Analysis; Synthesis and Biological Evaluation; Click Chemistry and Applications; Cancer therapeutics and mechanisms.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Reported open-access list prices
3,920.00 USD; 3,290.00 EUR; 2,620.00 GBP
APC list prices reported by OpenAlex, which obtains this information from DOAJ. Confirm current charges, taxes, waivers and eligibility with the publisher; this is not a fee quotation.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
A Multi‐Scale Computational Framework for Anti‐Persister Tuberculosis Drug Discovery
Said Moshawih, Anguraj Moulishankar, Chee Yan Choo, Khang Wen Goh et al.
2026-10 · DOI: 10.1111/cbdd.70408Triazole‐Linked Pyrimidine Nucleoside Dimers: Design, Synthesis, and Applications in Medicinal and Nucleic Acid Chemistry. Part IV
Dagmara Baraniak, Dariusz Wawrzyniak, Daniel Baranowski
2026-10 · DOI: 10.1111/cbdd.70407N 6 ‐Methyladenosine Demethylase FTO Protects Pancreatic ΒTC6 Cells From Cholesterol‐Triggered Damage by Regulating Nfatc4 : Insights From RNA ‐Seq Analysis
Pingping Hong, Yongjie Li, Jiandong Lin, Lingxiao Wang et al.
2026-10 · DOI: 10.1111/cbdd.70413Correction to “Rational Design, Synthesis, Biological Evaluation, and In Silico Study of N‐Cinnamamide/Benzamide‐(4‐(Substituted Phenyl)‐6‐(4‐Cyclohexylphenyl)pyrimidin‐2‐Yl) Derivatives as EGFR Inhibitors Targeting EGFRWT , EGFRT790M , and EGFRL858R / T790M / C797S in NSCLC ”
2026-10 · DOI: 10.1111/cbdd.70410Targeting a Leukemia‐Relevant Protein–Protein Interface: N‐Aryl Anthranilic Acids as Disruptors of the c‐Myb– CBP /p300 KIX Interaction
Haifa E. Alfassam, Emadeldin M. Kamel, Sarah I. Othman, Hanan M. Alharbi et al.
2026-10 · DOI: 10.1111/cbdd.70415An Anoikis‐Related Gene Signature Associated With Stromal Remodeling and Clinical Outcome in Gastric Cancer
Zhijun Fu, Lin Sun, Xing Wang, Biao Cheng et al.
2026-10 · DOI: 10.1111/cbdd.70411Integrative Single‐Cell Transcriptomics, Multi‐Omics Analyses, and Computational Pharmacology Reveal Macrophage Heterogeneity and the Putative THBS1 ‐ CD36 Axis in Coronary Atherosclerosis
Jianpeng Li, Xinrui Liu, Run Shi, Lin Yang et al.
2026-10 · DOI: 10.1111/cbdd.70399Cover Image
2026-10 · DOI: 10.1111/cbdd.70333Prevotella melaninogenica Alleviate Mycoplasma pneumoniae Infection Through the Butyrate Based on Multi‐Omic Analysis and Experimental Validation
Zhengyang Xue, Huiliang Xu, Ling Zhu, DeYu Zhao et al.
2026-09 · DOI: 10.1111/cbdd.70397Design, Synthesis, Antimycobacterial Evaluation, and In Silico Investigation of Benzisothiazole‐Based Hydrazide Derivatives as Potential Anti‐Tuberculosis Agents
Vivek Sharma, Arun Sharma, Ruchi Poria, Pardeep Kumar et al.
2026-09 · DOI: 10.1111/cbdd.70405Integrated Multi‐Omics and Radiogenomic Analysis Identifies S100B and ITGB5 as Complementary Candidate Biomarkers of Glioblastoma Heterogeneity
Xuhang Yang, Yusong Zhang, Yutuo Zheng, Jian Lin et al.
2026-09 · DOI: 10.1111/cbdd.70396Design, Synthesis, and Biological Evaluation of Anthracene Derivatives as Potent Antioxidants: Experimental, DFT , and Docking Studies
Mohamed R. Elmorsy, Menna Moustafa, Hassan A. Etman, Nashwa M. El‐Metwaly et al.
2026-09 · DOI: 10.1111/cbdd.70392Design, Synthesis, and Investigation of the Biological Activities of New Thiadiazole Derivatives With Anticancer Effects
Yusuf Özkay, Enes Bal, Berkant Kurban, Derya Osmaniye et al.
2026-09 · DOI: 10.1111/cbdd.70398Discovery of ER α‐Targeting Phytochemicals With In Vitro Cytotoxicity and Computational Prediction of Y 537 S Mutant Inhibition
Dejun Jiang, Oh Wook Kwon, Hanbin Joe, Euijeong Shin et al.
2026-09 · DOI: 10.1111/cbdd.70393Synthesis, Structural Characterization, and Investigation of Biological Effects of Novel Benzothiazole‐Triazole Derivatives Designed as AKT Kinase Inhibitors
Bilge Çiftçi, Zeynep Gülenç, Büşra Korkut Çelikateş, Derya Osmaniye et al.
2026-09 · DOI: 10.1111/cbdd.70404Targeting PIKfyve : Chemical Biology and Drug Discovery Insights
Athavan Alias Anand Selvam, Anamika Sharma
2026-09 · DOI: 10.1111/cbdd.70395An ALKBH3 Inhibitor HUHS199 Suppresses Proliferation of Glioblastoma Cells by Targeting 1‐Methyladenosine on GADD45A mRNA
Manami Yamada, Hiroaki Hase, Honoka Kitamura, Toshiya Morie et al.
2026-09 · DOI: 10.1111/cbdd.70385Discovery of Potent EGFR Inhibitors for Del19 and L858R / T790M Mutants Through Structure‐Based Virtual Screening and Biological Evaluation
Ting Xu, Yuchen Zhao, Mengfei Chen, Lijuan Zuo et al.
2026-09 · DOI: 10.1111/cbdd.70391Reviews
Community Reviews
Version History
October 10, 2026 at 1:26 am
October 2, 2026